ReviewFrontiers in oncology2018
Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment.
Review in Frontiers in oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Surgery for gastrointestinal metastases of malignant melanoma - a retrospective exploratory study.World journal of surgical oncology · 2019Trial
- Article
- Combinatory electric-field-guided deposition for spatial microparticles patterning.Materials today. Bio · 2024Article
- Advancements and Challenges in Personalized Therapy forJournal of clinical medicine · 2024Review
- Review
- SialidaseWorld journal of oncology · 2022Article
- Mefloquine induces ER stress and apoptosis in BRAFi-resistant A375-BRAFMolecular carcinogenesis · 2022Article
- Phenotyping in acute respiratory distress syndrome: state of the art and clinical implications.Current opinion in critical care · 2022Review
- Article
- Review
- Review
- Article
- Phenotypic Switching of B16F10 Melanoma Cells as a Stress Adaptation Response to Fe3O4/Salicylic Acid Nanoparticle Therapy.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Feasibility of Embedding a Scalable, Virtually Enabled Biorepository in the Electronic Health Record for Precision Medicine.JAMA network open · 2021Article
- Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice.OncoTargets and therapy · 2021Article
- Use of Nanoparticles in Delivery of Nucleic Acids for Melanoma Treatment.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Article
- (+)-BornylInternational journal of molecular sciences · 2020Article
- Protein Expression in Metastatic Melanoma and the Link to Disease Presentation in a Range of Tumor Phenotypes.Cancers · 2020Article
- Expression and predictive value of miR-489 and miR-21 in melanoma metastasis.World journal of clinical cases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite enormous international efforts, skin melanoma is still a major clinical challenge. Melanoma takes a top place among the most common cancer types and it has one of the most rapidly increasing incidences in many countries around the world. Until recent years, there have been limited options for effective systemic treatment of disseminated melanoma. However, lately, we have experienced a rapid advancement in the understanding of the biology and molecular background of the disease. This has led to new molecular classifications and the development of more effective targeted therapies adapted to distinct melanoma subtypes. Not only are these treatments more effective but they can be rationally prescribed to the patients standing to benefit. As such, melanoma management has now become one of the most developed for personalized medicine. The aim of the present paper is to summarize the current knowledge on melanoma molecular classification, predictive markers, combination therapies, as well as emerging new treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.